Short-Term Effects of Sacubitril/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease

Abstract

Background and Objective: Sacubitril/valsartan (SV) is an angiotensin receptor-neprilysin inhibitor that works by inhibiting the neprilysin enzyme as well as blocking angiotensin receptors. The benefits of using SV in congestive heart failure patients has been demonstrated in several clinical trials; however, limited data are available for dogs with heart failure. The aim of this study was to investigate the short-term effects of SV in comparison with ramipril in the standard therapy of symptomatic dogs suffering from myxomatous mitral valve disease (MMVD).Methods: In this prospective, randomized, single-blind study, 21 dogs with MMVD stage C were randomly assigned to received SV (20 mg/kg orally twice a day) or ramipril (0.125 mg/kg, orally once a day) in addition to pimobendan and furosemide. Echocardiography, electrocardiography, blood pressure, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and urinary aldosterone per creatinine ratio were obtained at baseline (D0) and at follow-up (4 weeks).Results: When comparing the percent change from baseline between groups, the left atrium to aortic root ratio (LA/Ao) and left ventricular internal diameter diastole normalized to body weight (LVIDDN) were significantly reduced in the SV group (P < 0.001 and P < 0.01, respectively). The end-diastolic volume index (EDVI), end-systolic volume index (ESVI), and stroke volume were lower in the SV group (P < 0.001, P < 0.05, and P < 0.01, respectively). No changes were observed between groups for NTproBNP, blood pressure, ECG parameters, and urinary aldosterone per creatinine ratio.Conclusion: The current study suggested that the short-term effects of SV can reverse myocardial remodeling, as inferred from several echocardiographic indices (i.e., the reduction in LA/Ao, LVIDDN, EDVI and ESVI) in dogs with MMVD stage C. These findings would support the use of SV in clinically symptomatic heart failure in dogs.

Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation

“…Besides reducing left heart dilation, SAC/VAL also preserved LV systolic function, as indicated by the significant increase in FS and EF compared with MR. These findings are consistent with previous studies of SAC/VAL in other cardiovascular diseases in experimental and clinical studies 17 , 25 – 27 . Furthermore, with the persistent MR in the MR vehicle-treated rats, the progressive LV expansion and annular dilatation can increase severity of MR suggested by El Sabbagh and colleagues 28 .…”

Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs

“…At baseline, M1, M3, and M6, an echocardiographic examination was performed on all animals without sedation using an ultrasound machine (M9, Mindray Medical, Bangkok, Thailand) equipped with phased array transducers (P10-4E and SP5-1E) by an experienced veterinarian, as previously described [ 14 ]. All echocardiographic examinations were performed by a single experienced veterinarian.…”

Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs

“…The stroke volume (SV) and cardiac output (CO) were calculated, while the heart rate (HR) was obtained from the ECG and was simultaneously recorded with the echocardiography. The intraobserver and interobserver variabilities of the echocardiographic parameters of the authors were as performed and published previously [ 16 ].…”